Verve Therapeutics Merges with Eli Lilly in Acquisition

Verve Therapeutics ( (VERV) ) has provided an announcement.

On June 16, 2025, Verve Therapeutics entered into a merger agreement with Eli Lilly, where Lilly will acquire Verve through a tender offer for $10.50 per share, plus a contingent value right of up to $3.00 per share. This acquisition aims to advance Verve’s gene editing programs for cardiovascular disease, with the potential to shift treatment paradigms from chronic care to one-time treatments, enhancing Lilly’s capabilities in cardiometabolic disease and genetic medicines.

The most recent analyst rating on (VERV) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Verve Therapeutics stock, see the VERV Stock Forecast page.

Spark’s Take on VERV Stock

According to Spark, TipRanks’ AI Analyst, VERV is a Neutral.

Verve Therapeutics’ stock is buoyed by strong technical momentum, despite challenges in financial performance and valuation. The company’s robust balance sheet offers some financial stability, but its unprofitability and negative P/E ratio are significant concerns. Investors should be cautious of the high-risk profile due to the negative margins and volatile nature of the biotechnology sector.

To see Spark’s full report on VERV stock, click here.

More about Verve Therapeutics

Verve Therapeutics, Inc. is a clinical-stage company focused on developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic therapies to single-course gene editing medicines. Its lead programs target key lipoprotein drivers of atherosclerosis, with VERVE-102 designed to permanently turn off the PCSK9 gene in the liver, initially for heterozygous familial hypercholesterolemia and ultimately for patients with established atherosclerotic cardiovascular disease.

Average Trading Volume: 3,504,889

Technical Sentiment Signal: Hold

Current Market Cap: $558.9M

Find detailed analytics on VERV stock on TipRanks’ Stock Analysis page.